{"id":392879,"date":"2020-12-03T10:22:57","date_gmt":"2020-12-03T15:22:57","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=392879"},"modified":"2020-12-03T10:22:57","modified_gmt":"2020-12-03T15:22:57","slug":"sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/","title":{"rendered":"Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020"},"content":{"rendered":"<h2>\nThe poster will be made available at SABCS.org on Wednesday, Dec. 9<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">COLUMBUS, Ohio, Dec.  03, 2020  (GLOBE NEWSWIRE) &#8212; Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision medicine metastatic breast cancer arena, today announced that it will share a poster and audio presentation at the virtual San Antonio Breast Cancer Symposium (SABCS) 2020 on the Phase 2 clinical study of its lead investigational drug, lasofoxifene, in combination with Eli Lilly and Company\u2019s FDA-approved CDK 4 and 6 inhibitor, abemaciclib.<\/p>\n<p>The abstract reviews the design of the study, which was announced in July and began dosing patients in October. As of Nov. 16, four of 13 U.S. centers are now enrolling and four subjects have begun study treatment.<\/p>\n<p>\n        <strong>Presentation Details:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Title<\/strong>: An Open-Label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination with Abemaciclib for the Treatment of Pre and Postmenopausal Women with Locally Advanced or Metastatic ER+\/HER2\u2212 Breast Cancer and Have an ESR1 Mutation<\/li>\n<li>\n          <strong>Presenters<\/strong><br \/>\n          <strong>:<\/strong><\/p>\n<ul>\n<li>Senthil Damodaran, M.D., Ph.D., assistant professor of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center<\/li>\n<li>Paul V. Plourde, M.D., vice president of oncology clinical development, Sermonix Pharmaceuticals<\/li>\n<li>Debu Tripathy, M.D., professor and chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center<\/li>\n<li>Simon Jenkins, Ph.D., vice president of operations, Sermonix Pharmaceuticals<\/li>\n<li>David Portman, M.D., founder and chief executive officer, Sermonix Pharmaceuticals<\/li>\n<\/ul>\n<\/li>\n<li>\n          <strong>Date and time: <\/strong>The poster will be made available online at <a href=\"https:\/\/www.sabcs.org\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>SABCS.org<\/u><\/a> on Wednesday, Dec. 9, at 8 a.m. Central Time<\/li>\n<li>\n          <strong>Session:<\/strong> Ongoing Trials Poster Session (OT9-01)<\/li>\n<\/ul>\n<p>The study is Sermonix\u2019s second <strong><em>E<\/em><\/strong><em>valuation of <\/em><strong><em>La<\/em><\/strong><em>sofox<\/em><strong><em>i<\/em><\/strong><em>fe<\/em><strong><em>n<\/em><\/strong><em>e in <\/em><strong><em>E<\/em><\/strong><em>SR1 Mutations<\/em> (ELAINE) study and known as ELAINE 2. It is assessing the safety and tolerability of lasofoxifene in combination with abemaciclib for treating women with locally advanced or metastatic ER+\/HER2- breast cancer and an ESR1 mutation. Sermonix is partnering with Tempus, a data-driven, precision-medicine technology company, to identify and enroll ELAINE 2 participants through genomic biomarker testing.<\/p>\n<p>\u201cSermonix is delighted to share a poster at SABCS 2020 highlighting the study in our collaboration with Eli Lilly and Company,\u201d said Dr. Paul Plourde. \u201cCombination therapy is an important treatment option in the ER+\/HER2- breast cancer setting, yet there is currently no approved therapy in the presence of ESR1 mutations. This safety study allows us to continue the effort toward addressing this area of significant unmet medical need.\u201d<\/p>\n<p>Preclinical models of invasive breast cancer at the University of Chicago have identified synergy between lasofoxifene, a selective estrogen receptor modulator (SERM), and a CDK 4 and 6 inhibitor, palbociclib, in the presence of ESR1 mutations.<\/p>\n<p>\u201cThe ELAINE 2 trial is a critical step toward confirming the efficacy of this combination in a larger study,\u201c said Dr. Senthil Damodaran. \u201cIt is important we continue the work of investigating combinations in the setting of ESR1 mutations, and making progress toward improving the prognosis for women with metastatic breast cancer.\u201d<\/p>\n<p>\n        <strong>About Lasofoxifene<\/strong><br \/>\n        <br \/>Lasofoxifene is an investigational, nonsteroidal selective estrogen receptor modulator (SERM), which Sermonix licensed globally from Ligand Pharmaceuticals Inc. (NASDAQ: LGND) and has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide. Lasofoxifene\u2019s bioavailability and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical need. Lasofoxifene\u2019s novel activity in ESR1 mutations was discovered at Duke University and Sermonix has exclusive rights to develop and commercialize the product in this area. Lasofoxifene, a potent, oral SERM could, if approved, play a critical role in the targeted precision medicine treatment of advanced ER+ breast cancer.<\/p>\n<p>\n        <strong>About Abemaciclib<\/strong><br \/>\n        <br \/>Abemaciclib (trade name Verzenio<sup>\u00ae<\/sup>) is a CDK4 and 6 inhibitor and the first and only oral tablet of its kind that can be taken every day for the treatment of HR+, HER2\u2013 metastatic breast cancer. It is indicated for the treatment of HR+, HER2- advanced or metastatic breast cancer, in combination with an aromatase inhibitor for postmenopausal women as initial endocrine-based therapy; in combination with fulvestrant for women with disease progression following endocrine therapy; or as a single agent for adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.<\/p>\n<p>\n        <strong>About Sermonix<\/strong><br \/>\n        <br \/>Sermonix Pharmaceuticals Inc. is a privately held biopharmaceutical company focused on the development of female-specific oncology products and is currently undertaking two Phase 2 clinical studies of lasofoxifene, its lead investigational drug. Sermonix Pharmaceuticals was founded in 2014 by David Portman, M.D., a leading clinical researcher and expert in women\u2019s health, menopause and selective estrogen receptor modulator (SERM) therapy. The Sermonix management team, led by Dr. Portman, has significant experience in all stages of the drug development and regulatory process. Paul Plourde, M.D., vice president of oncology clinical development, has many decades of experience in the oncology drug development arena. Barry Komm, Ph.D., chief scientific officer, is recognized for his expertise in SERM biology. Miriam Portman, M.D., is chief operating officer. Elizabeth Attias, M.M.Sc., Sc.D., chief strategy and development officer, has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph.D. vice president of operations, has over 30 years of experience in global drug development leadership. Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lambert\u2019s Pharmaceutical Division. Learn more at\u00a0<a href=\"https:\/\/sermonixpharma.com\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>https:\/\/sermonixpharma.com\/<\/u><\/a>.<\/p>\n<p>\u00a0<\/p>\n<p>Contact information:<br \/>David Portman, MD<br \/>CEO and Founder, Sermonix Pharmaceuticals<br \/><a href=\"mailto:dportman@sermonixpharma.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">dportman@sermonixpharma.com<\/a><br \/>614-582-6849<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjM3MSMzODU1MjI3IzUwMDA1MTg2MA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/c2efd861-c6c9-433c-b87b-cefb4d899e92\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The poster will be made available at SABCS.org on Wednesday, Dec. 9 COLUMBUS, Ohio, Dec. 03, 2020 (GLOBE NEWSWIRE) &#8212; Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision medicine metastatic breast cancer arena, today announced that it will share a poster and audio presentation at the virtual San Antonio Breast Cancer Symposium (SABCS) 2020 on the Phase 2 clinical study of its lead investigational drug, lasofoxifene, in combination with Eli Lilly and Company\u2019s FDA-approved CDK 4 and 6 inhibitor, abemaciclib. The abstract reviews the design of the study, which was announced in July and began dosing patients in October. As of Nov. 16, four of 13 U.S. centers are &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-392879","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The poster will be made available at SABCS.org on Wednesday, Dec. 9 COLUMBUS, Ohio, Dec. 03, 2020 (GLOBE NEWSWIRE) &#8212; Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision medicine metastatic breast cancer arena, today announced that it will share a poster and audio presentation at the virtual San Antonio Breast Cancer Symposium (SABCS) 2020 on the Phase 2 clinical study of its lead investigational drug, lasofoxifene, in combination with Eli Lilly and Company\u2019s FDA-approved CDK 4 and 6 inhibitor, abemaciclib. The abstract reviews the design of the study, which was announced in July and began dosing patients in October. As of Nov. 16, four of 13 U.S. centers are &hellip; Continue reading &quot;Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-03T15:22:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjM3MSMzODU1MjI3IzUwMDA1MTg2MA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020\",\"datePublished\":\"2020-12-03T15:22:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\\\/\"},\"wordCount\":950,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjM3MSMzODU1MjI3IzUwMDA1MTg2MA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\\\/\",\"name\":\"Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjM3MSMzODU1MjI3IzUwMDA1MTg2MA==\",\"datePublished\":\"2020-12-03T15:22:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjM3MSMzODU1MjI3IzUwMDA1MTg2MA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjM3MSMzODU1MjI3IzUwMDA1MTg2MA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/","og_locale":"en_US","og_type":"article","og_title":"Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020 - Market Newsdesk","og_description":"The poster will be made available at SABCS.org on Wednesday, Dec. 9 COLUMBUS, Ohio, Dec. 03, 2020 (GLOBE NEWSWIRE) &#8212; Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision medicine metastatic breast cancer arena, today announced that it will share a poster and audio presentation at the virtual San Antonio Breast Cancer Symposium (SABCS) 2020 on the Phase 2 clinical study of its lead investigational drug, lasofoxifene, in combination with Eli Lilly and Company\u2019s FDA-approved CDK 4 and 6 inhibitor, abemaciclib. The abstract reviews the design of the study, which was announced in July and began dosing patients in October. As of Nov. 16, four of 13 U.S. centers are &hellip; Continue reading \"Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-03T15:22:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjM3MSMzODU1MjI3IzUwMDA1MTg2MA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020","datePublished":"2020-12-03T15:22:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/"},"wordCount":950,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjM3MSMzODU1MjI3IzUwMDA1MTg2MA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/","name":"Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjM3MSMzODU1MjI3IzUwMDA1MTg2MA==","datePublished":"2020-12-03T15:22:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjM3MSMzODU1MjI3IzUwMDA1MTg2MA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjM3MSMzODU1MjI3IzUwMDA1MTg2MA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sermonix-to-present-poster-on-phase-2-study-of-lasofoxifene-in-combination-with-eli-lilly-and-companys-abemaciclib-at-virtual-san-antonio-breast-cancer-symposium-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company\u2019s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=392879"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392879\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=392879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=392879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=392879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}